Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
dose-dependent response across 3, 6, and 9 mg arms Phase 3 T2D : HbA1c reductions up to 2.15% versus placebo in Chinese population trials Phase 1b/2 data : Earlier dose-finding studies establishing the efficacy and tolerability profile Global development : Ongoing clinical trials outside China, but no FDA approval or submission as of early 2026 Limitation : Primary clinical data from Chinese population
Community-reported protocols typically pair melanotan-1 with brief UV exposure to accelerate and deepen the melanogenic response
A significant finding was the elevated levels of pyroglutamic acid in malignant cells, which was linked to the overexpression of CHAC1, resulting in the production of pyroglutamic acid and cysteinyl-glycine
Suitable for all skin types and ideal for both men and women
Liu J, Kang R, Tang D
US$ 22.20
US$ 23.42
US$ 24.28
US$ 25.29
US$ 22.52
US$ 29.31
